Teva stops testing migraine drug as cluster headache treatmentApprovals, Breakthrough Therapy Status, Clinical Trials, Cluster Headaches, FDA, Huntington's Disease, Migraine, R&DTeva Pharmaceutical Industries Ltd. will stop developing the migraine drug Ajovy for treating cluster headaches after finding the treatment was unlikely to meet the main goal of a late-stage trial. Read more April 23, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-04-23 09:24:212019-04-23 13:16:19Teva stops testing migraine drug as cluster headache treatment